Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Coal tar 5% in Generic Unguentum M cream
1305020C0AAGNGN
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 5%/Betamethasone valerate 0.025% 5% in WSP
1304000F0AAEAEA
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar 5%/Salicylic acid 5% in Betamethasone valerate 0.1%
1305020I0AAAMAM
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar 6% / Salicylic acid 3% in Emulsifying ointment
1305020C0AAEPEP
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 6% / Salicylic acid 6% in White soft paraffin
1305020C0AAGCGC
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 6% in Yellow soft paraffin
1305020C0AAEXEX
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 6%/Salicylic acid 3% in Cetomacrogol (Formula A)
1305020C0AAGPGP
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 8%/Salicylic acid 2% in Betamethasone valerate 0.1%
1305020I0AAAFAF
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar extract 1% cream
1305020C0AABJBJ
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar extract 5% / Allantoin 2% cream
1305020C0AABABA
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar extract 5% / Allantoin 2% lotion
1305020C0AABBBB
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 10% / Salic acid 5% in Betameth val 0.1% oint
1305020I0AAAHAH
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar soln 10% / Salicylic acid 10% in Gen Unguen M crm
1305020C0AAGUGU
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 10% / Salicylic acid 2% in Gen Unguentum M crm
1305020C0AAFUFU
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 10% / Salicylic acid 3% in Emulsifying oint
1305020C0AAFWFW
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 10% / Salicylic acid 6% in Gen Unguen M crm
1305020C0AAHIHI
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 10% in Betamethasone valerate 0.025% oint
1304000F0AACRCR
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar soln 10% in Betamethasone valerate 0.1% oint
1304000F0AADMDM
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar soln 12% / Salicylic acid 2% in Emulsifying oint
1305020C0AAHAHA
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 12% / Salicylic acid 3% in Emulsifying oint
1305020C0AAFTFT
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 12%/Salicylic acid 4% in Yellow soft paraffin
1305020C0AAFMFM
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 15% in Betamethasone valerate 0.025% oint
1304000F0AADHDH
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar soln 2% / Salicylic acid 2% in Emulsifying oint
1305020C0AAGJGJ
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 2% / Salicylic acid 2% in White soft paraffin
1305020C0AAGHGH
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 20% / Salicylic acid 6% in Gen Unguentum M crm
1305020C0AAGLGL
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.